DNA topoisomerase I (topo I) has been firmly established as the molecular target of the camptothecin group of anticancer drugs. These drugs include camptothecin, topotecan, 9-amino-camptothecin, and irinotecan (1 ). Many of them are now in clinical trials and are showing activity against a wide variety of solid human malignancies (2 ).